Navigation Links
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
Date:2/3/2010

TOKYO and EDISON, N.J., Feb. 3 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

It is estimated that more than 900,000 fatal and non-fatal VTE events occur in the U.S. annually, and approximately 300,000 deaths are related to VTE per year.(i)  In Europe, VTE affects more than 750,000 people in six major European countries (France, Germany, Italy, Spain, Sweden, UK) annually, and approximately 370,000 deaths are related to VTE per year in these countries.(ii)

"The incidence of VTE is predicted to double by 2050,(iii)" said Harry R. Buller, M.D., Professor of Internal Medicine, chairman of the Department for Vascular Medicine at the Academic Medical Center, Amsterdam and chairman of the Steering Committee for HOKUSAI VTE.  "Based on what we've seen in Phase II and other trials, edoxaban shows promise as an agent to help fulfill the need for treatment options that are safe, effective and more convenient than the current standard of care, which requires extensive monitoring, careful dose adjusting and may have the potential for various drug and food interactions."

The primary efficacy endpoint for HOKUSAI VTE is the recurrence of symptomatic VTE (i.e., the composite of D
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
2. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
3. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
11. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... Kan. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Trust Alliance (HITRUST) under its Common Security Framework ... Enterprise Security and Privacy Manager, "We appreciate this ... level of commitment that this certification signifies. Our ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s ...
(Date:8/21/2014)... , Aug. 21, 2014  ACI Clinical ... for independent Data Monitoring Committees. Using ... 30 percent over industry standard costs and receive ... industry leader in committee services. Leveraging ... recruitment and contracting, charter development, statistical programming and ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... statement was issued today by the law firm of Barroway ... hereby given that a class action lawsuit was filed in ... California on behalf of purchasers of the securities of SciClone ... "Company"), who purchased or otherwise acquired SciClone,s securities between May ...
... NVAX ) President and CEO Dr. Rahul Singhvi today ... Secretary Kathleen Sebelius and other public health officials announcing a ... vaccines to prevent the spread of infectious diseases and issued ... initiatives: Define and strengthen FDA regulatory processes ...
Cached Medicine Technology:Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 3NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:8/22/2014)... August 22, 2014 Millennium Treatment ... in Lantana, FL, recently launched a new website. ... for information can now find Millennium Treatment Group ... just went live at the beginning of July. ... facility can be found on the website. There’s ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Beat ... how they can use natural methods to completely cure ... caught the attention of Shane Michaels, prompting an investigative ... that affects the skin, it can still be extremely ... reports Michaels. “The intense itching and pain that it ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
(Date:8/22/2014)... factor receptor (EGFR) mutations found in the circulating free ... cell lung cancer (NSCLC) patients correlates well with the ... tyrosine kinase inhibitor (TKI) therapy is approved for EGFR ... standard for determining mutation status is with DNA derived ... not available. A more abundant and less invasive source ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
... SAN JOSE, Calif., Sept. 2 MAQUET Cardiovascular ... complaint filed by Terumo,Cardiovascular Systems Corp. (Terumo CSC) ... District of California. The complaint alleges that,MAQUET,s VASOVIEW ... In April 2008, MAQUET filed patent infringement ...
... SANTA YNEZ VALLEY, Calif., Sept. 2 Platinum Performance,client McLain ... Summer Olympics in Beijing, China, on August 19, as "probably ... sport.", Winning the first ever jump-off in Olympic Games ... the Team Show Jumping title at the Hong Kong,Olympic Equestrian ...
... Sept. 2 MBF Healthcare,Acquisition Corp. (Amex: ... purpose,acquisition company, announced today the amendment of ... of Critical Homecare Solutions,Holdings, Inc. ("CHS"), based ... February 6, 2008 (the "Stock Purchase Agreement"). ...
... 2 Herley Industries,Inc. (Nasdaq: HRLY ), a ... solutions for the defense, aerospace and medical,industries worldwide, announced ... Jefferies & Company, Inc., as its financial,advisor to assist ... Myron Levy, Chairman and CEO, said, "We are pleased ...
... Help Payers and Providers Contain Costs and ... Improve Patient Outcomes Together, ... of Innovent Oncology, a service division that offers a first-time,opportunity ... designed specifically for the complexity of cancer,care. With a unique ...
... showed benefits even a year after routine was stopped, ... -- Exercise may help treat memory problems in adults, ... focused on 138 people age 50 and older at ... activity program led to modest improvements in cognitive function ...
Cached Medicine News:Health News:MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems 2Health News:Platinum Performance Clients Take Home Medals for the USA 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives 2Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Exercise May Help Prevent Age-Related Memory Loss 2
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... forceps are extremely delicate and if repairs ... they can easily be damaged beyond repair ... endoscopes. , On the other hand, with ... can have a virtually indefinite lifespan. The ...
Medicine Products: